| Ytd | -48.32% | |
| 1y | -45.04% |
| Open | 0.78 | Prev Close | 0.77 | Low | 0.77 | High | 0.78 | Mkt Cap | 32.79M |
| Vol | 11.58K | Avg Vol | 105.70K | EPS | -1.45 | P/E | -0.54 | Forward P/E | -2.14 |
| Beta | 1.54 | Short Ratio | 0.47 | Inst. Own | 5.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.91 | 200-d Avg | 1.18 | 1yr Est | 12.08 |
MIRA News
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "C
Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain an
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver
Data show Mira-55 does not produce the central nervous system effects associated with THC and acts t
Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-respon
Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strate
Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value P
Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokine
Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normaliza
Edmonton, Alberta--(Newsfile Corp. - May 6, 2026) - Visionstate Corp. (TSXV: VIS) today reported its
Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a valida
Edmonton, Alberta--(Newsfile Corp. - March 18, 2026) - Visionstate Corp. (TSXV: VIS) today provided
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced periphera
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA - Get Free Report) saw a large increase in short interest i
Edmonton, Alberta--(Newsfile Corp. - February 19, 2026) - Visionstate Corp. (TSXV: VIS) today announ
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Assoc
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no appr
Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the co
Shares of Porch Group, Inc. (NASDAQ: PRCH) rose sharply in pre-market trading after the company rep